Skip to content
OpenCapital
Get started

Rapid Micro Biosystems RPID Increase (decrease) in contract liabilities and current deferred income

Increase (decrease) in contract liabilities and current deferred income at other companies

Charles River Laboratories logo
Charles River LaboratoriesCRL
$5.2M+528%
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
——

Other financials

Income statement

See full
Revenue$8.0M+11.1%
Gross profit$371.0K-8.2%
Operating income-$13.9M-18.8%
Net income-$14.3M-26.7%
EPS (diluted)-$0.31-19.2%

Balance sheet

See full
Cash & equivalents$14.1M-26.8%
Total debt$23.8M+301%
Total equity$20.4M-68.9%
Total assets$62.4M-27.0%

Cash flow

See full
Operating cash flow-$15.1M-66.1%
CapEx$394.0K+23.5%
Free cash flow-$15.5M-64.7%

Valuation

See full
Market cap$86.19M-43.8%
Enterprise value$95.86M-31.7%
P/S2.5×-2.6×

Profitability

See full
Operating margin-144.2%-12.7pp
Net margin-145.8%-5.0pp
FCF margin-110.5%-14.9pp

Returns & leverage

See full
Return on equity-116.7%-620pp
Debt / equity1.2×+1.1×
Current ratio2.6×-2.0×

Where this comes from

Reported directly by Rapid Micro Biosystems in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.

The official record: Rapid Micro Biosystems’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rapid Micro Biosystems's increase (decrease) in contract liabilities and current deferred income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rapid Micro Biosystems's increase (decrease) in contract liabilities and current deferred income?
Rapid Micro Biosystems (RPID) reported increase (decrease) in contract liabilities and current deferred income of $1.9M in Q1 2026.
How has Rapid Micro Biosystems's increase (decrease) in contract liabilities and current deferred income changed year-over-year?
Rapid Micro Biosystems's increase (decrease) in contract liabilities and current deferred income increased by 474.8% year-over-year, from -$507K to $1.9M.
What is the long-term trend for Rapid Micro Biosystems's increase (decrease) in contract liabilities and current deferred income?
Over 3 years (2021 to 2025), Rapid Micro Biosystems's increase (decrease) in contract liabilities and current deferred income has grown at a 19.5% compound annual growth rate (CAGR), from -$1.12M to -$1.91M.